CLAIMS

1. Use of a compound which at least partially inhibits the activity of the p53 protein for the preparation of a pharmaceutical composition intended for the treatment and/or the prevention of neurodegenerative diseases.

2. Use according to Claim 1, characterized in that it is a compound which acts on the synthesis of the p53 protein, at the transcriptional, translational or post-translational levels, and/or on the binding of p53 to DNA.

3. Use according to Claim 2, characterized in that the compound is a double-stranded nucleic acid comprising all or part of the site for binding of p53 to DNA.

4. Use according to Claim 2, characterized in that the compound is a nucleic acid encoding a mutated form of the p53 protein capable of antagonizing the activity thereof.

5. Use according to Claim 2, characterized in that the compound is an antisense nucleic acid capable of reducing the levels of expression of the p53 protein, at the transcriptional or translational level.

6. Use according to Claim 5, characterized in that the antisense nucleic acid is a DNA encoding an antisense ribonucleic acid capable of inhibiting the translation of the p53 cellular mRNA.

7. Use according to Claims 3 to 5,

characterized in that the nucleic acid forms part of a vector.

8. Use according to Claim 7, characterized in that the nucleic acid forms part of a viral vector.

9. Recombinant virus comprising, inserted into its genome, at least one nucleic acid encoding a mutated form of the p53 protein capable of antagonizing the activity thereof, and/or a nucleic acid comprising all or part of the site for binding of p53 to DNA and/or an antisense nucleic acid capable of reducing the levels of expression of the p53 protein, at the transcriptional or translational level.

10. Recombinant virus according to Claim 9, characterized in that it is an adenovirus, a retrovirus, an adeno-associated virus, or the herpes virus.

11. Recombinant virus according to Claim 10, characterized in that it is an adenovirus.

12. Recombinant virus according to one of Claims 7 to 10, characterized in that the nucleic acid comprises all or part of the sequence SEQ ID No. 2 or active variants thereof.

13. Recombinant virus according to one of Claims 9 to 12, characterized in that it comprises several identical or different nucleic acids as defined in Claims 3 to 5.

14. Recombinant virus according to one of Claims 9 to 13, characterized in that it is a defective

virus.

15. Pharmaceutical composition comprising at least one recombinant virus according to one of Claims 9 to 14.

add a2